ILCA Annual Conference 2021 - Final Programme 2-5 September 2021 I
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
ILCA Annual Conference 2021 2-5 September 2021 I www.ilca2021.org Final Programme
Table of Contents
P-3 P-15
Letter of Welcome Sponsors, Media and other Partners
P-4 P-17
About ILCA
ILCA 2021 Scientific Programme
P-14 P-18
Industry Sponsored Symposia
Practicalities
2 I ILCA ANNUAL CONFERENCE 2021
Letter of Welcome
Dear ILCA members, colleagues, and friends,
It is our immense pleasure to invite you to attend the Virtual 15th Annual Conference of the
International Liver Cancer Association (ILCA) from 2nd to 5th September 2021.
The Governing Board and the Education Committee of ILCA have worked over the year to bring
together eminent experts from around the globe with the goal of improving our knowledge on
liver cancer, from causes and mechanisms to prevention and patient care.
Virtually again this year, our broad community will have the opportunity to share knowledge,
learn and network during four days around the latest advances in basic, translational, and clinical
research on liver cancer.
The programme will provide you with a great educational experience and hopefully will allow you
to interact with colleagues from different countries and with different research interests.
We look forward to welcoming you all virtually as we work together to advance liver cancer
science and care to offer true hope to patients.
Warm regards,
On behalf of the ILCA Governing Board
Bruno Sangro, MD, PhD Augusto Villanueva, MD, PhD
ILCA President ILCA Executive Secretary
3 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
THURSDAY, 2 SEPTEMBER 2021 - CEST TIME
14:00 - 14:15 WELCOME ADDRESS
ILCA President, Bruno Sangro, MD, PhD (Spain)
14:15 - 16:15 RARE LIVER TUMORS PRE-CONFERENCE WORKSHOP
Chairs: Ghassan K. Abou-Alfa, MD (USA), Jessica Zucman-Rossi, MD, PhD (France)
• Fibrolamellar Carcinoma
- Clinical aspects of fibrollamelar hepatocellular carcinoma
Ghassan K. Abou-Alfa, MD (USA)
- Basic/Translation aspects of fibrolamelar hepatocellular carcinoma
Sanford Simon, PhD (USA)
• Cholangio Mix Tumor
- Clinical management of mixed liver tumors
Myron Schwartz, MD (USA)
• Hepatoblastoma
- Clinical aspects of hepatoblastoma
Tanya Trippett, MD (USA)
- Basic aspect
Jessica Zucman-Rossi, MD, PhD (France)
• Rare Hepatic Tumors
- Rare hepatic tumors: What you need to know
Valerie Paradis, MD, PhD (France)
• Patient Advocacy
- Patient advocacy for patients with fibrolamellar HCC
Mark Furth, PhD (USA)
4 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
THURSDAY, 2 SEPTEMBER 2021 - CEST TIME
16:45 -17:45 SINGLE TOPIC WORKSHOP
• Molecular Diversity in HCC
Amaia Lujambio, MD, PhD (USA), Andrew Zhu, MD, PhD (USA)
• Systemic Therapy
Jean-Charles Nault, MD, PhD (France), Bristi Basu, MD, PhD (UK)
• Surgery in the management of HCC: Role of Surgeons and of the Radiologists
Eric Vibert, MD, PhD (France) , Lewis Roberts, MB, ChB, PhD (USA)
• Radiology
Riccardo Lencioni, MD, EBIR, FSIR (Italy) , Tae Kyoung Kim, PhD, FRCPC (Canada)
17.45 - 18.30 ILCA /EASL JOINT SYMPOSIUM
Chairs: Tim Meyer, BSc, MBBS, PhD, FRCP (UK), Maria Reig, PhD (Spain)
Speakers::
Speakers
• CAR T Cell Therapy for HCC
Mitchell Ho, PhD (USA)
• Innovative approached to CAR T Cell Therapy – lessons from haematology
Claire Roddie,MD, PhD (UK)
• Identification of bacteria-derived HLA-bound peptides in melanoma
Shelly Kalaora, PhD (Germany)
5 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
FRIDAY, 3 SEPTEMBER 2021 - CEST TIME
14:00 - 14:30 BASIC STATE OF THE ART: TELOMERES AND CANCER
Chair: Amaia Lujambio, MD, PhD (USA)
Speaker:
• Telomere-induced DNA damage as anticancer strategy
Maria Blasco, PhD (Spain)
14:45 - 15:45 YOUNG INVESTIGATOR SESSION
Chair: Laura Kulik,
Kulik MD (USA)
Speakers:
4 oral presentations submitted by young reserachers followed by Q&A time.
•
O-01 Peroxiredoxin 2 drives NASH progression towards hepatocellular carcinoma by
perturbing hepatic lipid metabolism
Eugénie Schaeffer (France)
•
O-02 Cabozantinib enhances anti-PD1 efficacy and elicits a neutrophil-based immune response
in murine models: implications for human HCC
Roger Esteban-Fabró (Spain)
•
O-03 Weight variations and level of estrogen exposure predict the evolution of
hepatocellular adenomas
Alix Demory (France)
•
O-04 Immune profiling of hepatocellular carcinoma using deep-learning on histological slides
Qinghe Zeng (USA)
16:00 - 17:00 TOP-SCORED POSTERS: BEST BASIC / TRANSLATIONAL POSTER SESSION
Chairs: Jessica Zucman-Rossi, MD, PhD (France), David Pinato, MD, PhD (UK)
Speakers:
•
P-01 Temporal and Spartial Dynamics of Hepatic Stellate Cell Activation in Intrahepatic
Cholangiocarcinoma.
Liqin Zhu (USA)
•
P-02 Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular
carcinoma.
Paula Restrepo (USA)
•
P-03 Autoimmunity and cancer immunosurveillance in the biliary tree.
Jonathan Pol (France)
•
P-04 Inflamed class of HCC: an expansion of the immune class based upon new molecular
features.
Florian Castet (USA)
6 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
FRIDAY, 3 SEPTEMBER 2021 - CEST TIME
16:00 - 17:00 TOP-SCORED POSTERS: BEST BASIC / TRANSLATIONAL POSTER SESSION
•
P-05 Phenotypic characteristics of the tumour microenvironment in primary and secondary
hepatocellular carcinoma.
Petros Fessas (UK)
• P-06 New therapeutic targets in cisplatin-resistant hepatoblastoma.
Théo Hirsch (France)
•
P-07 Notch Pathway Activation Drives Immune Evasion in Hepatocellular Carcinoma.
Katherine Lindblad (USA)
•
P-09 Deep sequencing of HCC endothelium reveals an active role in immunosuppression and
highlights the endo nucleotidase CD73 as a potential therapeutic target.
Rosemary Faulkes (UK)
•
P-53 A humanized Claudin-1-specific monoclonal antibody for treatment of hepatocellular
carcinoma.
Marion Muller (France)
•
P-27 Increased hepatic pregnane X receptor protein expression negatively correlates with
tight junction proteins and is a target for therapy in patients with hepatocellular carcinoma.
Balasubramaniyan Vairappan (India)
17:15 - 18:00 JUNIOR INVESTIGATOR AWARDS CEREMONY
In this session the International Liver Cancer Association is going to recognise 4 individuals for their
outstanding contributions to advancing liver cancer research.
ILCA President: Bruno Sangro, MD, PhD (Spain)
ILCA Executive Secretary: Augusto Villanueva, MD, PhD (USA)
ILCA Treausurer: Tim Meyer, MD, PhD (UK)
ILCA President Elect: Jessica Zucman-Rossi, MD, PhD (France)
7 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
FRIDAY, 3 SEPTEMBER 2021 - CEST TIME
BASIC SCIENCE SYMPOSIUM: WHAT HAS SINGLE CELL GENOMICS CONTRIBUTED TO OUR
18:00 - 18:45
UNDERSTANDING OF LIVER CANCER?
Chairs: Robert T. Schwabe, MD (USA), Amaia Lujambio, MD, PhD (USA)
Speakers:
• Single cell genomics and response to therapies in hepatocellular carcinoma
Xin Wei Wang, PhD (USA)
• Ploidy heterogeneity and HCC prevention
Hao Zhu, MD, PhD (USA)
• Tumor microenvironment in the development and progression of cholangiocarcinoma
Silvia Affo, PhD (Spain)
19:00 - 19:30 YOUNG INVESTIGATOR CLUB
The ILCA Young Investigator Steering Committee ( Y-ILCA) will present the main goals of this new
young committee like promoting young investigators in ILCA, communicate the activities of ILCA to
young investigators, build a young investigators active community and participate in the organization
of activities for young investigators in ILCA educational activities, including the annual conference.
The Y-ILCA is composed by:
• Laura Kulik, USA - Governing Board mentor
• David Pinato, UK
• Marina Bárcena Varela, USA
• Marco Sanduzzi, Spain
• Monika Lewinska, Denmark
• Amanda Craig, USA
• Ken Liu, Australia
Join the session and get to know more about the Y-ILCA committee and how you could participate on
the activities by discussing with them.
8 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
SATURDAY, 4 SEPTEMBER 2021 - CEST TIME
12:45 - 13:00 DAILY WRAP-UP
Augusto Villanueva, MD, Phd (USA), Laura Kulik, MD (USA)
GENERAL SESSION 1: MOLECULAR PATHOGENESIS, CELL BIOLOGY, AND
14:00 - 15:00
TRANSLATIONAL RESEARCH
Chairs: Stephanie Roessler, MD, PhD (Germany), Amaia Lujambio, MD, PhD (USA
(USA))
Speakers:
• O-05 Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma
Philipp K. Haber (USA)
• O-06 A novel microenvironment-based classification of intrahepatic cholangiocarcinoma
Daniela Sia (USA)
• O-07 Single-cell RNA sequencing unravels the immunosuppressive landscape and tumor
heterogeneity of HBV-associated hepatocellular carcinoma
Daniel Ho (USA)
• O-08 Cytokine Gradients in Human Hepatocellular Carcinoma Microenvironment Regulate
Innate Lymphoid Cells
Bernd Heinrich (Germany)
CLINICAL STATE OF THE ART: PAST, PRESENT, AND FUTURE OF TRANSPLANT
15:15 - 15:45
ONCOLOGY
Chair: Gonzalo Sapisochin, MD, PhD (Canada)
Speaker:
• Past, present, and future of transplant oncology
Vincenzo Mazzaferro, MD, PhD (Italy)
16:00 - 17:00 TOP-SCORED POSTERS: BEST CLINICAL POSTER SESSION
Chairs: Eric Vibert, MD, PhD (France), Maxime Ronot, MD, PhD (France)
Speakers:
• P
-41 Early antibiotic exposure is not detrimental to response to immune checkpoint inhibitor
therapy for hepatocellular carcinoma: evidence from an observational study.
Petros Fessas (UK)
9 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
SATURDAY, 4 SEPTEMBER 2021 - CEST TIME
16:00 - 17:00 TOP-SCORED POSTERS: BEST CLINICAL POSTER SESSION
• P
-42 A multicentred phase II clinical trial on serial combination of Yttrium 90-resin microspheres
(Y90-RE) and chemotherapy for locally advanced intra-hepatic cholangiocarcinoma (ICC).
Stephen Lam Chan (China)
• P
-38 Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and
tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular
carcinoma.
Thi Thu Nga Nguyen (France)
• P
-34 Sorafenib in extended patient populations in real-world clinical practice: Baseline
characteristics from OPTIMIS and GIDEON.
Masatoshi Kudo (Japan)
• P
-36 A Pilot Study of the combination of Immune Checkpoint Inhibition with Ablation in Subjects
with Hepatocellular Carcinoma; an evaluation of Trans-arterial Chemoembolization (TACE) and
Radiofrequency Ablation (RFA).
Rebecca Wetzel (USA)
• P
-20 Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver: A Spanish
multicentre study.
Sonia Pascual (Spain)
• P
-21 Prognosis of patients with other primary tumors associated to hepatocellular carcinoma.
Miriam Celada-Sendino (Spain)
• P
-55 Lifestyle changes in DAA-cured Hepatitis C patients with advanced liver disease included
in a nurse-led liver cancer screening program.
Gemma Iserte (Spain)
• P
-29 Dual filtration system for isolation and single cell RNA sequencing of circulating tumor
cells and clusters in hepatocellular carcinoma: A pilot study.
Vincent Chen (USA)
17:15 - 18:00 ILCA TUMOR BOARD
Chair: Augusto Villanueva, MD, PhD (USA)
Speaker :
• Case 1 HCC
• Case 2 Cholangiocarcinoma
Pierre Nahon, MD, PhD (France)
Panel of experts:
• Sasan Roayaie, MD, FACS (USA)
• Ann-Lii Chen, MD, PhD (Taiwan)
• Thierry Debaere, MD (France)
• Angela Lamarca, MD, PhD, MSc (Spain)
10 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
SATURDAY, 4 SEPTEMBER 2021 - CEST TIME
17:15 - 18:00 GENERAL SESSION 2: EPIDEMIOLOGY, STAGING AND PROGNOSIS
Chairs: David Pinato, MD, PhD (UK), Anjana Pillai, MD (USA)
Speakers:
• O-09 Characteristics of unresectable HCC patients in the new era of immunotherapy: first
results from the ELITor study, based on the French prospective multicenter CHIEF cohort.
Eric Nguyen-Khac (France)
• O-10 Mailed Outreach Strategy Significantly Increases Hepatocellular Carcinoma Surveillance
Utilization: A Multi-Site Randomized Clinical Trial.
Amit Singal (USA)
• O-11 Cachexia is Prevalent in Patients with Hepatocellular Carcinoma and Associated with
Worse Prognosis.
Nicole Rich (USA)
• O-12 ERS: A simple, user-friendly model to predict early recurrence after surgical resection for
hepatocellular carcinoma.
Charlotte Constantin (France)
• O-13 The Association of Sustained Virologic Response on Outcomes in Patients with
Hepatocellular Carcinoma with Hepatitis C.
Neehar Parikh (USA)
• O-14 A Prognostic Score Using Gadoxetic Acid–enhanced MRI To Predict Overall Survival After
Curative Resection For Hepatocellular Carcinoma.
Hong Wei (China)
11 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
SUNDAY, 4 SEPTEMBER 2021 - CEST TIME
12:45 - 13:00 DAILY WRAP-UP
Augusto Villanueva, MD, Phd (USA), Amaia Lujambio, MD, PhD (USA)
14:00 - 15:30 GENERAL SESSION 3: DIAGNOSIS, IMAGING AND BIOMARKERS
Chairs: Amit Singal,, MD (USA), Nicole Rich, MD, MSCS (USA)
Speakers:
• O-15 Detection of Early-Stage HCC by Abbreviated MRI: Multicenter Validation Against
Surgical Pathology.
Takeshi Yokoo (USA)
• O-16 Limitations of non-invasive radiological criteria for the diagnosis of advanced
hepatocellular carcinoma.
Alexa Childs (UK)
• O-17 Hepatocellular carcinoma early detection using Magnetic Resonance Imaging is cost-
effective in French high-risk patients with cirrhosis.
Pierre Nahon (France)
• O-18 Imbrave150: Albumin-Bilirubin (ALBI) grade analyses in a phase III study of Atezolizumab
(ATEZO) + Bevacizumab (BEV) versus Sorafenib (SOR) in patients (PTS) with unresectable
Hepatocellular Carcinoma (HCC).
Masatoshi Kudo (Japan)
• O-19 Circulating Tumor Cell-Based mRNA Scoring System for Prognostication of
Hepatocellular Carcinoma - Translating HCC Tissue-based mRNA Profiling into a Non-invasive
Setting.
Yi-Te Lee (USA)
• O-20 Undernutrition in patients with primary hepatocellular carcinoma.
Hitomi Takada (Japan)
15:45 - 16:45 ILCA DEBATES
Chair: Richard Finn, MD (USA)
• HCC down-staging to surgical therapies
- Plenty of room
Laura Crocetti, MD, PhD, EBIR (Italy)
- Still too many questions
Laura Kulik, MD (USA)
• Early transition to systemic therapies in patients at stage BCLC-B
- Too early to recommend
Jens Ricke, MD (Germany)
- It is time to transition systemic therapy to BCLC stage B
Lipika Goyal, MD (USA)
12 I ILCA ANNUAL CONFERENCE 2021ILCA 2021 Scientific Programme
SUNDAY, 4 SEPTEMBER 2021 - CEST TIME
16:45 - 18:00 CLINICAL SCIENCE SYMPOSIUM: THE FUTURE OF COMBINATION THERAPIES IN HCC
Chairs: Lorenza Rimassa, MD, PhD (Italy), Stephen Lam Chan, MD (Hong-Kong)
Speakers:
• Triple systemic therapies in HCC: Rationale, prospects and ongoing trials
Robin Kate Kelley, MD (USA)
• Combination therapies and adverse events: pearls in clinical management
David Pinato, MD, PhD (UK)
• Clinical trials design in area or immune therapies: AASLD consensus
Josep Maria Llovet, MD, PhD (USA)
18:15 - 19:45 GENERAL SESSION 4: THERAPY & CLINICAL TRIALS IN 2021
Chairs: Robin Kate Kelley, MD (USA), Ann-Lii Chen, MD, PhD (Taiwan)
Speakers:
• O-21 Nivolumab (NIVO) in sorafenib (SOR)-naive and -experienced patients with advanced
hepatocellular carcinoma (aHCC): 5-year follow-up from CheckMate 040 cohorts 1 and 2.
Joerg Trojan (Germany)
• O-22 Data from the third dose cohort and expansion phase of a Phase 1 trial of ADP-A2AFP
SPEAR T-cells for patients with hepatocellular carcinoma and other cancer types expressing
alpha-fetoprotein.
Bruno Sangro (Spain)
• O-23 Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in
patients with hepatocellular carcinoma.
David Pinato (UK)
• O-24 Tailored approach for the treatment of hepatocellular carcinoma within Milan criteria
developed on advanced fibrosis/cirrhosis by multibipolar radiofrequency ablation or liver
resection: a retrospective multicentric study on 1060 patients.
Jean-Charles Nault (France)
• O-25 Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical
practice: Updated interim analysis of the prospective observational REFINE trial.
Ho Yeong Lim (South Korea)
• O-26 Systematic review and meta-analysis of RCT (2002-2020): is etiology relevant for
immunotherapies?
Philipp K. Haber (USA)
19:45 - 20:00 FAREWELL ADDRESS
2021-2023, Jessica Zucman-Rossi, MD, PhD (France)
ILCA President 2021-2023,
13 I ILCA ANNUAL CONFERENCE 2021Practicalities
ABOUT THE CONFERENCE
• ILCA
The International Liver Cancer Association (ILCA) is the only international organisation devoted exclusively
to liver cancer research for experts from all related disciplines.
ILCA aims at creating an international multidisciplinary forum to address the increasing incidence of liver
cancer through the enhancement of the knowledge of clinical, translational, and basic research, ultimately
creating novel preventive, diagnostic and therapeutic strategies.
The purpose for which ILCA was established is the advancement of medical education, research, and
clinical care in the field of liver cancer.
Please come and visit us at the ILCA virtual booth. The ILCA Team will be pleased to meet you and provide
you with any information you may want to know on ILCA activities, membership, and future ILCA events.
Information is also available at
www.ilca-online.org Intern a tional Liver Cancer A s soci at io n
• Accreditation
The International Liver Cancer Association’s 15th Annual Conference being the second ILCA virtual
conference this year has been accredited by the European Accreditation Council for Continuing Medical
Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only
those hours of credit that he/she spent in the educational activity.
• Junior Investigator Awards
ILCA will recognise extraordinary achievements in liver cancer research across disciplines and support the
professional development of four junior investigators in training. The awards will be given for novel and
significant liver cancer research across the fields of basic cancer research; translational cancer research;
cancer diagnosis; the prevention of cancer; or cancer patients treatment.
• Official Language
The official language of the conference is English. Simultaneous translation will not be provided.
14 I ILCA ANNUAL CONFERENCE 2021Sponsors, Media and other Partners
ILCA warmly thanks all the sponsors for their involvement in ILCA 2021
Supporters
Principal Sponsor
Conference Sponsors
Conference Supporters
ILCA Industry Partners
15 I ILCA ANNUAL CONFERENCE 2021Sponsors, Media and other Partners
Media Partners
Partner Societies
• American Association for the Study of Liver Diseases (AASDL)
• American Society of Clinical Oncology (ASCO)
• Argentinian Society of Hepatology (SAHE)
• Asian Pacific Association for the Study of the Liver (APASL)
• Asia-Pacific Primary Liver Cancer Expert Association
• Canadian Association of Gastroenterology (CAG)
• Canadian Association for the Study of the Liver (CASL)
• Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
• European-African Hepato-Pancreato-Biliary Association (E-AHPBA)
• European Association for Cancer Research (EACR)
• European Association for the Study of the Liver (EASL)
• European Society for Medical Oncology (ESMO)
• European Society of Surgical Oncology (ESSO)
• French Association for the Study of the Liver (AFEF) ,
• International Liver Transplantation Society (ILTS)
• Japan Society of Clinical Oncology (JSCO)
• Japanese Society of Medical Oncology (JSMO)
• Korean Association for Clinical Oncology (KACO)
• Korean Association for the Study of the Liver (KASL)
• Korean Cancer Association (KCA)
• Korean Liver Cancer Association (KLCA)
• Korean Association of Hepato-Biliary-Pancreatic Surgery (KAHBPS)
• Latin American Association for the Study of the Liver (ALEH)
• Liver Transplant Society of India (LTSI)
• Society of Interventional Oncology (SIO)
• Stockholm Liver Week
• United European Gastroenterology (UEG)
16 I ILCA ANNUAL CONFERENCE 2021About ILCA
Liver cancer is rapidly increasing worldwide, triggering widespread interest and strong focus surrounding
all aspects of this disease. Given the naturally multidisciplinary nature of liver cancer, however, no
single association has before the International Liver Cancer Association (ILCA) adopted a transversal
approach to liver cancer by connecting expertise from interrelated fields, research and treatment
levels. In response to this shortfall, ILCA was established in 2006 and is currently the only international
organisation devoted exclusively to liver cancer across disciplines.
Our Mission
ILCA strives to advance research in the pathogenesis, prevention, and treatment of liver cancer, by
promoting novel pathogenic, diagnostic, and therapeutic interventions for liver cancer, and taking
a transversal approach to research. Indeed, ILCA brings together scientists, physicians and allied
professionals from all interrelated fields and countries and strives to welcome and incorporate
individuals involved in all the scientific disciplines devoted to basic, translational and clinical
research in liver cancer as individual members. ILCA actively partners with other professional
associations involved in any aspect related to liver cancer research, with the objective to join
efforts for the benefit of science.
Joining Our Community
We invite you to discover more about ILCA on www.ilca-online.org, as well as to connect with our
expanding group of interested physicians, scientists, and allied health professionals from various
fields and from around the world.
Membership to ILCA not only provides you with exclusive benefits such as reduced registration
rates to our events, exciting networking and educational opportunities and active involvement in
association affairs; it also helps us to develop our activities and our reach to advance liver cancer
research and care.
ILCA Governing Board
Executive Committee Council
President Sasan Roayaie, USA
Bruno Sangro, Spain Laura Kulik, USA
Jeong Min Lee, Republic of Korea
Executive Secretary
Amit Singal, USA
Augusto Villanueva, USA
Eric Vibert, France
Treasurer Amaia Lujambio, USA
Tim Meyer, UK Michiie Sakamoto, Japan
Lorenza Rimassa, Italy
President Elect R. Kate Kelley, USA
Jessica Zucman-Rossi, France Stephen Chan, Hong Kong
www.ilca2021.org I www.ilca-online.org
17 I ILCA ANNUAL CONFERENCE 2021Industry Sponsored Symposia
Industry Symposia at ILCA 2021 give you the chance to discuss and exchange knowledge on data and
products with our industry sponsors.
THURSDAY, SEPTEMBER 2, 2021
18:45 - 19:45 CET INCYTE INDUSTRY SPONSORED SYMPOSIUM
Time for Precision Medicine for Patients with Cholangiocarcinoma
The esteemed faculty will give their expert perspectives on cholangiocarcinoma (CCA), including the burden of disease,
considerations around molecular profiling and the emergence of precision medicine for patients with advanced CCA.
Speakers:
• Professor Bruno Sangro, MD, PhD; Clinica Universidad de Navarra, Pamplona, Spain
• Dr Cindy Neuzillet, MD, PhD; Institut Curie, Saint Cloud, Paris, France
• Professor Albrecht Stenzinger, MD; University Hospital Heidelberg, Heidelberg, Germany
• Dr Joachim Mertens, MD; University Hospital Zürich, Zürich, Switzerland
19:45 - 20:45 CET ROCHE INDUSTRY SPONSORED SYMPOSIUM
Making waves in unresectable HCC: a new standard of care?
Recent approvals and emerging data with cancer immunotherapy combinations have inspired new optimism in the
landscape of unresectable HCC, with the changing tide reaching beyond clinical trial centres and into everyday
practice. With novel treatment strategies now available, we must focus on optimising the patient experience. Deep
diving into updated data, exploratory subgroup analyses and a real-world patient case, we will provide expert insight
and guidance on what clinicians need to know in order to make informed and tailored treatment decisions.
Speakers:
• Professor Bruno Sangro, MD, PhD; Clinica Universidad de Navarra, Pamplona, Spain
• Lorenza Rimassa, Associate Professor of Medical Oncology; Humanitas University and IRCCS Humanitas
Research Hospital, Italy
FRIDAY, SEPTEMBER 3, 2021
13:00 - 14:00 CET BAYER INDUSTRY SPONSORED SYMPOSIUM
Treating Beyond Clinical Trials: Connecting Real-world Data on Sorafenib and Regorafenib to Clinical Experience
With the increasing complexity of the unresectable HCC treatment landscape, therapeutic choices are becoming more
and more challenging, particularly for those subgroups of patients who are commonly seen in clinical practice but who
are typically excluded from clinical trials. Our global panel of experts will explore the nuances of treatment choice in
these patients and engage with the data that supports the different therapeutic options.
Speakers:
• Markus Peck-Radosavljevic, MD, MBA; Klinikum Klagenfurt am Wörthersee, Austria
• Pierre Gholam, MD, FAASLD, AGAF; Case Western Reserve University, United States
• Madappa Kundranda, MD, PhD; Banner MD Anderson Cancer Center, United States
• Changhoon Yoo, MD; University of Ulsan College of Medicine, Korea
18 I ILCA ANNUAL CONFERENCE 2021Industry Sponsored Symposia
SATURDAY, SEPTEMBER 4, 2021
13:00 - 14:00 CET EISAI INDUSTRY SPONSORED SYMPOSIUM
The role of first-line monotherapy in a uHCC combination market
A panel of leading experts will discuss the role of LENVIMA® (lenvatinib) monotherapy in a rapidly evolving treatment
landscape, followed by a live Q&A. With combination therapies expected to become the standard of care in first-line
uHCC, our panel will cover a variety of topics including patient selection, clinical considerations, and the latest real-
world evidence.
Speakers:
• Professor Josep Llovet, Professor of Research-ICREA, Liver Unit, IDIBAPS-Hospital Clínic of Barcelona (Spain)
and Director of the Liver Cancer Program and Full Professor of Medicine at Mount Sinai School of Medicine, New
York, USA.
• Dr Stephen Chan, Associate (Clinical) Professor at the Department of Clinical Oncology of the Chinese University
of Hong Kong.
• Professor Arndt Vogel, Professor for gastrointestinal oncology at the Hannover Medical School
SUNDAY, SEPTEMBER 5, 2021
13:00 - 14:00 CET BOSTON SCIENTIFIC INDUSTRY SPONSORED SYMPOSIUM
Evidence & Clinical Application of SIRT in Early & Intermediate HCC
Beginning with more advanced stage patients to early-stage HCC with low tumour burden. From bridging and
downstaging to lobectomy and segmentectomy, the versatility of TheraSphere has been proven in more than 50
publications, and more data is on its way…
Speakers:
• Professor Eric Vibert, Liver Surgeon, Paul Brousse Hospital, Villejuif, France
• Professor Daniel Seehofer, HPB Surgeon, Universitätsklinikum Leipzig, Leipzig, Germany
• Professor Juliene Edeline, Medical Oncologist, Centre Eugène Marquis, Rennes, France
• Professor Jens Theysohn, Interventional Radiologist, Universitätsklinikum Essen, Essen, Germany
▶ Disclaimer
This ILCA Annual Final Brochure has been produced using author-supplied copies. Editing has been restricted to minor spelling
corrections where appropriate, otherwise every effort has been made to reproduce the abstracts as originally submitted. The
organiser and publishers assume no responsibility for any injury and/or damage to persons or property as a matter of product
liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in
the material herein. In view of rapid advances in medical sciences, independent verification of diagnoses and drug doses is
recommended.
19 I ILCA ANNUAL CONFERENCE 2021#ILCA21 App ▶ www.ilca2021.org ▶ www.ilca-online.org
You can also read
